| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | 0.0034 | 0.9 |